Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE +0.23%, DAX +0.20%, CAC40 +0.19%

Jul 29 ,2025

  • Synopsis

    • European equity markets set to open higher, whilst Asian equities mostly lower Tuesday. Hang Seng leading China market declines. Japan benchmarks extending recent pullback. Korean stocks seeing mild gains while Australia and Taiwan indexes turning lower. S&P 500 futures steady afterhours.

    • US and China to resume negotiations on Tuesday after officials left first day of talks without speaking to reporters. Commerce Secretary Lutnick said 90-day extension of US-China tariff deadline is likely outcome of talks, adding weight to SCMP article that first reported details of an extension. US reportedly making efforts to smooth path towards Trump-Xi meeting, though Trump later denied he was seeking summit. Press sources have highlighted US goodwill measures such as freezing tech export controls while Reuters sources noted Taiwan President Lai Ching-te to delay diplomatically sensitive US stopover.

    • In politics, Chancellor Merz hosts Jordan's King Abdullah II and there's the World Conf. of Speakers of Parliament (through Thu). Also, EU's Hansen attends the Pichelsteinerfest in Regen and is panellist at 13:00CET title 'The Common Agricultural Policy of today and tomorrow - competitive, productive, and resilient'. Norway's PM Støre at open public meeting in Rjukan at 19:30CET.

    • In central banks, ECB publishes at 10:00CET latest results of consumer expectations survey.

    • Economic releases due today: Spain Q2 preliminary GDP, Jun retail sales, UK Jun mortgage approvals, M4 money supply, Sweden Q2 preliminary GDP, Norway Jun retail sales, Belgium Q2 preliminary GDP.

    • In earnings news, DACHs names kicked off the session with Redcare Pharmacy (RDC.GR), SIG Combibloc Group (SIGN.SW) and Sika Group (SIKA.SW) reporting Q2/H1 earnings. In France, yesterday after markets closed EssilorLuxottica (EL.FP) and Rexel (RXL.FP) released Q2/H1 earnings, whilst this morning Air Liquide (AI.FP), Orange (ORA.FP), Amundi (AMUN.FP) and Sopra Steria Group (SOP.FP) issued earnings for the half year.

    • In Southern Europe, Acciona (ANA.SM) and Gestamp Automoción (GEST.SM) released H1 earnings results. Elsewhere, Koninklijke Philips (PHIA.NA) reported Q2 earnings with results above expectations and increased FY25 adj EBITA margin guidance range by 50 bps. Other notable names due to report today includes L'Oreal (OR.FP), Kering (KER.FP), Ferrovial (FER.SM), Logitech International (LOGN.SW), AstraZeneca (AZN.LN), Barclays (BARC.LN), and Games Workshop Group (GAW.LN).

  • Politics/Macro/World News

    • EU, US Rush to Clinch Final Details and Lock In Trade Deal - Bloomberg

    • Donald Trump's EU oil and gas deal is 'pie in the sky', energy experts warn - FT

    • ECB staff accuse Christine Lagarde of running 'unaccountable legal fortress' - FT

    • Rising UK food prices turn cash-strapped shoppers away from high street - The Guardian

  • Top company news

    • Earnings/updates

      • Benelux

        • PHIA.NA (Koninklijke Philips) -- reports Q2 adj EPS €0.36 vs consensus €0.27; increases FY25 adj EBITA margin guidance range by 50 bps

      • France

        • EL.FP (EssilorLuxottica) -- reports H1 adjusted net income €1.80B ex-items vs FactSet €1.82B

        • RXL.FP (Rexel) -- reports H1 net income €261.6M vs consensus €299.4M; confirms FY guidance

        • SOP.FP (Sopra Steria Group) -- reports H1 net income €142.0M, +15% vs year-ago €123.2M

        • VCT.FP (Vicat) -- reports H1 net income €102M, (2%) vs year-ago €104M

        • TRACT.FP (Teract)- - reports preliminary FY revenue €895.2M vs guidance €900-950M and year-ago €894.7M

        • AMUN.FP (Amundi) -- reports Q2 adjusted net income €334M vs StreetAccount €354.1M

        • AI.FP (Air Liquide) -- reports H1 EPS €3.12 vs consensus €3.11

        • ORA.FP (Orange) -- reports Q2 EBITDAaL €3.20B vs consensus €3.17B; adjusts FY25 EBITDAaL growth guidance upward

        • TFI.FP (TF1) -- reports Q2 net income €63M vs year-ago €66M; confirms FY25 guidance

      • DACHs

        • SIKA.SW (Sika Group) -- reports H1 net income CHF554.4M vs StreetAccount CHF601.3M

        • TMV.GR (TeamViewer) -- reports Q2 adjusted EBITDA €84.0M vs FactSet €79.4M [4 est, €76.2-82M]

        • RDC.GR (Redcare Pharmacy) -- reports Q2 net income €8.9M, including items

        • UN0.GR (Uniper) -- reports preliminary H1 adjusted EBITDA €379M vs year-ago €1.74B; confirms FY guidance

        • FORN.SW (Forbo Holding) -- reports H1 EPS CHF23.70 vs year-ago CHF34.36

        • SMHN.GR (SÜSS MicroTec) -- reports preliminary H1 revenue €266.4M; adjusts FY margin guidance

        • HYQ.GR (Hypoport) -- reports preliminary Q2 EBIT ~€7.4M vs FactSet €7.1M [1 est]

        • LEHN.SW (LEM Holding) -- reports Q1 net income CHF2.0M vs FactSet CHF4.1M [2 est, CHF4-4.2M]

        • RSGN.SW (R&S Group Holding) -- reports preliminary H1 revenue CHF206.3M vs year-ago CHF109.9M

        • SIGN.SW (SIG Combibloc Group) -- reports H1 net income €136.1M vs FactSet €127.4M [2 est, €126.1-128.7M]

        • WAF.GR (Siltronic) -- reports Q2 EBITDA €86.4M vs FactSet €67.9M [6 est, €57.8-80.0M]; FY25 guidance refined due to adjusted fx assumptions

        • TTK.GR (Takkt) -- reports H1 EPS (€0.02) vs year-ago €0.11

        • DRW3.GR (Drägerwerk) -- confirms preliminary H1/Q2 earnings

      • Southern Europe

        • ANA.SM (Acciona) -- reports H1 net income attributable €526M vs FactSet €493M [1 est]; reaffirms FY guidance (post EU close 28-Jul)

        • ANE.SM (Corporación Acciona Energías Renovables) -- reports H1 net income attributable €455M vs FactSet €494.5M [2 est, €484-505M] (post EU close 28-Jul)

        • GEST.SM (Gestamp Automoción) -- reports H1 net income €75M vs FactSet €69.5M [2 est, €68-71M]; reaffirms FY guidance

        • THEON.NA (Theon International) -- issues H1 trading update: reports preliminary H1 EPS €0.48 vs year-ago €0.41

        • UNI.SM (Unicaja Banco) -- reports H1 net income €338M, +114% vs year-ago €158M

      • Nordics

        • TOBII.SS (Tobii) -- reports Q2 EPS SEK0.02 vs FactSet SEK0.12 [2 est, (SEK0.01)-0.25]

        • RECSI.NO (REC Silicon) -- reschedules the publication of its H1 results to 22-Aug; cites timing of EGM

      • Also due to report today includes:

        • Earnings:

          • Benelux:Allfunds Group (ALLFG.NA), Basic-Fit (BFIT.NA), Havas (HAVAS.NA)

          • France: L'Oreal (OR.FP), Kering (KER.FP), Gaztransport & Technigaz (GTT.FP), Verallia (VRLA.FP), Imerys (NK.FP), Clariane (CLARI.FP), M6-Metropole (MMT.FP), Tarkett (TKTT.FP), Thermador Groupe (THEP.FP), SMCP (SMCP.FP), Euroapi (EAPI.FP)

          • Germany: TeamViewer (TMV.GR)

          • Italy: TERNA Rete Elettrica Nazionale (TRN.IM), Infrastrutture Wireless Italiane (INW.IM), Banca Generali (BGN.IM), Amplifon (AMP.IM), Brembo (BRE.IM), Cementir Holding (CEM.IM), Piaggio & C (PIA.IM)

          • Other: Bank of Ireland Group (BIRG.ID)

          • Portugal: Corticeira Amorim (COR.PL)

          • Spain: Ferrovial (FER.SM), Endesa (ELE.SM), Grifols (GRF.SM), Prosegur Compania de Seguridad (PSG.SM)

          • Sweden: Storytel (STORY.B.SS)

          • Switzerland: Logitech International (LOGN.SW), Forbo Holding (FORN.SW),

          • UK: AstraZeneca (AZN.LN), Barclays (BARC.LN), Games Workshop Group (GAW.LN), ConvaTec Group (CTEC.LN), UNITE Group (UTG.LN), Croda International (CRDA.LN), Shaftesbury Capital (SHC.LN), Inchcape (INCH.LN), Canal+ (CAN.LN), Morgan Sindall Group (MGNS.LN), Greggs (GRG.LN), Forterra (FORT.LN), Restore (RST.LN), Essentra (ESNT.LN), Sthree (STEM.LN), NWF Group (NWF.LN), Staffline Group (STAF.LN)

        • Trading Update:

          • France: Compagnie des Alpes (CDA.FP), Inventiva (IVA.FP), SergeFerrari Group (SEFER.FP)

          • UK: A.G. BARR (BAG.LN), Tristel (TSTL.LN)

        • CMD/events: Tristel (TSTL.LN)

    • M&A

      • HSBA.LN (HSBC Holdings) -- Banco BTG Pactual buys HSBC's Uruguay business for $175M

      • VIV.FP (Vivendi) -- Bolloré seeks annulment of the AMF decision requiring the filing of a public buyout offer on the shares of Vivendi within a six-month timeframe

      • EQT.SS (EQT AB) -- and CPP Investments to acquire NEOGOV from Warburg Pincus and Carlyle

      • VRLA.FP (Verallia) -- BWGI announces result of tender offer for Verallia

      • SLR.SM (Solaria Energia) -- Stonepeak completes the acquisition of an interest in Solaria's land platform dedicated to renewables, Generia Land, S.L.

      • RLF.SW (RELIEF THERAPEUTICS Holding) -- Relief Therapeutics executes binding term sheet for proposed combination with NeuroX at equity value of CHF100M

      • SEM.PL (Semapa) -- completes acquisition of Imedexa for €148M plus earnout

      • INSE.LN (Inspired) -- board strongly recommends shareholders to accept, or procure the acceptance of HGGC's offer as soon as possible

      • ARES (Ares Management Corp.) -- Ares Management establishes joint venture with Savion to invest in U.S. solar power generation

      • DG.FP (VINCI SA) -- VINCI Energies agrees to acquire Zimmer & Hälbig for an undisclosed sum

      • EZE.SM (Grupo Ezentis) -- issues convertible bonds with a total par amount of €1.1M to Global Tech Opportunities 30 as part of previously disclosed agreement

      • AURE.FP (Aurea) -- Lebronze Alloys to acquire M Lego from Aurea for an undisclosed sum

    • Healthcare

      • APLS (Apellis Pharmaceuticals) -- FDA approves Apellis Pharmaceuticals' EMPAVELI (pegcetacoplan) as first treatment for C3G or primary IC-MPGN in patients 12 years and older to reduce proteinuria

      • GLPG.NA (Galapagos) -- SEC filing: SCHEDULE 13D/A (Filed by EcoR1 Capital, LLC)

      • NYXH.BB (Nyxoah) -- announces DREAM pivotal study data for the Genio system published in Journal of Clinical Sleep Medicine

      • CYAD.BB (Celyad Oncology) -- announces €1M private placement

      • XVIVO.SS (Xvivo Perfusion) -- announces delay in CE approval for heart perfusion solution and supplement

    • Other

      • INTRUM.SS (Intrum) -- CEO Andrés Rubio to step down

      • ALFEN.NA (Alfen) -- appoints Michael Colijn as CEO, effective 1-Oct-25; to succeed Marco Roeleveld

      • UBSG.SW (UBS Group) -- UBS orders bankers to reduce sales of complex currency derivatives after heavy losses by clients - FT

      • ASM.NA (ASM International) -- completes share buyback program of up to €150M

      • ORA.FP (Orange) -- to expand credit services in Africa in partnership with JUMO

      • WISE.LN (Wise Plc) -- Wise confirms scheme and all special resolutions passed in connection with proposed primary listing transfer

      • VPK.NA (Royal Vopak) -- completes share buyback program 2025

      • Intraday themes include potential delay of SFDR review into 2026; Serapta denies connection to 8-year old death (28-Jul)

      • Rexel Q2 US Same Day sales +8.2%

  • Key rating changes

    • Upgrades

      • HEIJM.NA (Heijmans) -- upgraded to outperform from neutral at Oddo

    • Downgrades

      • FRVIA.FP (Forvia) -- to hold from buy at Deutsche Bank (timing uncertain)

      • SMHN.GR (SÜSS MicroTec) -- to hold from buy at Deutsche Bank

      • KOA.NO (Kongsberg Automotive) -- to hold from buy at ABG Sundal Collier

      • METSB.FH (Metsa Board) -- to sell from reduce at Inderes

      • LGEN.LN (Legal & General Group) -- downgraded to neutral from outperform at Mediobanca

  • Data

    • Nikkei (1.03%) to 40577.57

    • Hang Seng (1.04%) to 25295.81

    • Shanghai Composite +0.02% to 3598.59

    • S&P futures +9.8 vs prior close of 6422.8

    • €-$ (0.0008) or (0.07%) to 1.1582

    • $-¥ (0.27) or (0.18%) to 148.29

    • €-¥ (0.41) or (0.24%) to 171.73

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE